February 13, 2018 / 1:17 PM / 3 months ago

BRIEF-MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study

Feb 13 (Reuters) - MEI Pharma Inc:

* MEI PHARMA INTERIM DATA REVIEW SUPPORTS CONTINUATION OF CLINICAL STUDY EVALUATING ME-344 IN PATIENTS WITH BREAST CANCER

* MEI PHARMA INC - INTERIM STUDY DATA SHOW THAT ME-344 WAS GENERALLY WELL-TOLERATED

* MEI PHARMA - BASED ON INTERIM STUDY RESULTS, IT WAS DETERMINED THAT COMPLETING ENROLLMENT OF STUDY OF ME-344 IN COMBINATION WITH BEVACIZUMAB IS WARRANTED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below